MAHA summit highlights innovations reshaping American healthcare

• A study found that nearly 95% of viral TikTok videos promoting Korean skincare and "glass skin" make misleading claims. • Researchers analyzed viral content to determine how often skincare benefits were exaggerated or unsupported.

• Scientists at the Institute of Animal Virology (IAV) in Kerala are developing an early-warning system to forecast dengue trends and anticipate outbreaks. • The project utilizes artificial intelligence to improve medical imaging, clinical decision-making, and the development of drugs and vaccines.

• ANI Pharmaceuticals will present data from its uveitis trial and diabetic macular edema analyses via an on-demand poster. • The company plans to share results from the SYNCHRONICITY trial during an encore presentation on Jan. 21, 2027.

• Hospitals in England are experiencing shortages of common medications, including paracetamol, co-codamol, and the blood pressure drug ramipril. • The health department issued serious shortage protocols to ensure patients can still access ramipril despite its limited supply.

• The Trump administration reshaped U.S. biomedical research by implementing funding cuts and delays to National Institutes of Health (NIH) grants. • These delays impacted long-term grants that are typically awarded for multiple years and paid out annually to cover lab work and staff.

• FDA nominee Dr. Heidi Overton testified before the Senate on Thursday regarding her views on vaccines and abortion. • Dr. Overton stated that the MMR vaccine is safe, effective, and "not lethal," contradicting previous claims made by President Trump.

• The Centers for Medicare & Medicaid Services announced that Medicare Advantage and Medicare Prescription Drug Programs are expected to remain stable in 2027. • Weighted average Medicare Advantage premiums are projected to fall more than 16% from 2026 to 2027, while average prescription drug premiums in those plans are expected to drop 38%.

• Three top U.S. federal health officials will join over 900 rare disease leaders at the 2026 NORD Rare Diseases and Orphan Products Breakthrough Summit from October 25–27 in Washington, D.C. • Attendees will include Kyle Diamantas, the Acting Commissioner of Food and Drugs at the U.S. Food and Drug Administration.

• NanoViricides, Inc. filed its annual report detailing the Phase II clinical trials for NV-387, a broad-spectrum antiviral drug. • The company is targeting unmet medical needs for MPox and Ebola, noting that no approved drugs currently exist for the treatment of MPox Clade I or Clade II.

• NanoViricides, Inc. filed its Annual Report on Form 10-K with the SEC, detailing the progress of its antiviral drug NV-387. • The company is conducting Phase II trials for NV-387 to treat Mpox and Ebola, noting that there is currently no approved drug for Mpox Clade I or Clade II.

• Senators questioned FDA nominee Heidi Overton during a hearing regarding her positions on vaccines, vapes, and abortion. • Overton frequently avoided giving direct answers to the senators' questions during the session.